Recce is pioneering a new class of synthetic anti-infectives, including RECCE® 327 (R327), RECCE® 435 (R435), and RECCE® 529 (R529). These innovations are critical in combating antibiotic-resistant superbugs, a global health crisis. Our technology has been recognised by the WHO and U.S. FDA, earning R327 a Qualified Infectious Disease Product designation, offering 10 years of market exclusivity post-approval​.

The company has made significant strides in multiple clinical trials. We completed a Phase I/II trial of R327 for urinary tract infections and reported promising results. R327 has shown broad-spectrum antibacterial efficacy and safety across several applications, including diabetic foot infections and burn wound infections​. The company's ability to generate positive clinical data across multiple indications positions it strongly for future market opportunities.

Recce has secured substantial non-dilutive funding from various governments, including AUD $54.9 million in advanced overseas funding from the Australian government and USD $2 million from the U.S. Department of Defense to support its burn wound program. Additionally, the company successfully raised up to AUD $12.4 million to further its clinical developments, demonstrating solid investor confidence​.

Recce has developed strategic partnerships, such as its collaboration with PT Etana Biotechnologies in Indonesia, aimed at accelerating clinical trials and market penetration in Southeast Asia. This partnership opens up access to a significant population base across ASEAN, further enhancing the company's growth potential​.